Protein Phosphatase 2A (PP2A) is a highly conserved serine/threonine phosphatase and one of the most abundant phosphatases in mammalian cells. It belongs to the PPP (phosphoprotein phosphatase) family and functions as a critical regulator of cellular phosphorylation states. PP2A exists as a heterotrimeric complex consisting of a catalytic subunit (PP2Ac), a scaffolding A subunit (PP2A-A), and a regulatory B subunit that determines substrate specificity and localization. The human PP2A catalytic subunit is encoded by genes PPP2CA and PPP2CB, while multiple B-subunit variants (designated as B, B', and B'' families) provide regulatory diversity. This architectural flexibility allows PP2A to dephosphorylate over 300 known substrates across diverse cellular compartments and pathways, making it a central hub for cellular signal transduction and homeostasis.
Function and Biology
...
PP2A Protein
Overview
Protein Phosphatase 2A (PP2A) is a highly conserved serine/threonine phosphatase and one of the most abundant phosphatases in mammalian cells. It belongs to the PPP (phosphoprotein phosphatase) family and functions as a critical regulator of cellular phosphorylation states. PP2A exists as a heterotrimeric complex consisting of a catalytic subunit (PP2Ac), a scaffolding A subunit (PP2A-A), and a regulatory B subunit that determines substrate specificity and localization. The human PP2A catalytic subunit is encoded by genes PPP2CA and PPP2CB, while multiple B-subunit variants (designated as B, B', and B'' families) provide regulatory diversity. This architectural flexibility allows PP2A to dephosphorylate over 300 known substrates across diverse cellular compartments and pathways, making it a central hub for cellular signal transduction and homeostasis.
Function and Biology
PP2A functions as a broad-specificity phosphatase that counterbalances protein kinase signaling by removing phosphate groups from serine and threonine residues on target proteins. The A subunit serves as a platform that bridges the catalytic subunit with various B regulatory subunits, which direct the complex to specific substrates and subcellular locations. This modular architecture enables precise temporal and spatial regulation of dephosphorylation events. PP2A participates in multiple fundamental cellular processes including cell cycle progression, apoptosis, protein synthesis, cytoskeletal dynamics, and signal transduction. It regulates key kinases including Akt/PKB, MAPK, GSK-3β, and tau kinase, making it essential for maintaining cellular phosphorylation balance. The phosphatase activity of PP2A is tightly controlled through post-translational modifications, including methylation of the catalytic subunit C-terminus (regulated by methyltransferases LCMT1 and demethylase PME-1) and phosphorylation of regulatory subunits, ensuring that its activity remains appropriately calibrated to cellular needs.
Role in Neurodegeneration
PP2A dysfunction represents a critical mechanism in multiple neurodegenerative diseases. In Alzheimer's disease, reduced PP2A activity contributes to tau hyperphosphorylation—a pathological hallmark characterized by excessive phosphorylation of tau protein leading to microtubule destabilization and neurofibrillary tangle formation. Several studies have demonstrated decreased PP2A activity in Alzheimer's disease brain tissue and cerebrospinal fluid. Similarly, in Parkinson's disease, PP2A dysregulation impairs the dephosphorylation of α-synuclein, promoting its aggregation into pathogenic Lewy bodies. In Huntington's disease, altered PP2A function disrupts the regulation of mutant huntingtin protein phosphorylation and contributes to proteolytic processing. ALS research has identified PP2A dysfunction affecting phosphorylation of TDP-43 and FUS proteins, two key pathological proteins in this disease. The reduction in PP2A activity appears mediated by oxidative stress, aberrant protein-protein interactions with disease-associated proteins, and altered expression of regulatory subunits.
Molecular Mechanisms
The loss of PP2A activity in neurodegeneration involves several interconnected mechanisms. Oxidative stress characteristic of these diseases impairs PP2A catalytic subunit function through direct oxidation of catalytic residues and disruption of C-terminal methylation patterns. Amyloid-beta and phosphorylated tau can directly inhibit PP2A activity in Alzheimer's disease models. Disease-associated proteins may sequester B-regulatory subunits or prevent proper PP2A complex assembly, reducing catalytic efficiency. Additionally, alterations in the expression of methyltransferases and demethylases that regulate PP2A methylation status contribute to reduced enzymatic activity. Calcium dysregulation and mitochondrial dysfunction further compromise PP2A-mediated signaling. These mechanisms collectively shift the phosphorylation equilibrium toward hyperphosphorylation of disease-associated substrates including tau, α-synuclein, and other protein aggregation-prone factors.
Clinical and Research Significance
PP2A represents an attractive therapeutic target for neurodegenerative diseases. Activating PP2A through compounds like DPH (dihydro-pyrones) or by enhancing its methylation status shows promise in preclinical models of Alzheimer's disease and Parkinson's disease by reducing pathological protein phosphorylation. Research into PP2A-activating compounds and methylation modulators continues as potential disease-modifying therapies. Understanding PP2A dysfunction provides mechanistic insights linking hyperphosphorylation, protein aggregation, and neuronal death.
Related Entities
[[Tau Protein]] - major PP2A substrate hyperphosphorylated in Alzheimer's disease
[[Alpha-Synuclein]] - PP2A substrate relevant to Parkinson's disease pathology
[[GSK-3 Beta]] - kinase counterbalanced by PP2A activity
[[Protein Phosphorylation]] - central PP2A regulatory mechanism
[[Alzheimer's Disease]] - neurodegenerative condition with